Work

MASLD VCTE-C cohort: a prospective multicenter study linking liver fibrosis to cardiovascular outcomes in patients with metabolic dysfunction–associated steatotic liver disease

Year: 2026
Type: article
Study design: Study Protocol
Abstract: Background Metabolic dysfunction–associated steatotic liver disease (MASLD) is associated with increased risk of cardiovascular disease (CVD). The MASLD vibration-controlled transient elastography (VCTE)-C cohort is designed to examine the relationships among VCTE-derived hepatic measures, coronary artery calcification, and long-term cardiovascular outcomes in patients with MASLD. Methods This prospective, multicenter observational cohort will enroll 880 patients with VCTE-defined MASLD (controlled attenuation parameter [CAP] ≥248 dB/m) across 11 tertiary hospitals in the Republic of Korea. Additional eligibility criteria include at least one of the following: (i) type 2 diabetes; (ii) prediabetes; or (iii) obesity accompanied by at least one additional cardiovascular risk factor. Baseline assessments include noninvasive surrogates for liver fibrosis (fibrosis-4 index and liver stiffness measurement by VCTE) and steatosis (CAP by VCTE), coronary artery calcium scoring by noncontrast cardiac computed tomography, cardiometabolic profiling, and 10-year cardiovascular risk estimation primarily using the PREVENT equations, with the Pooled Cohort Equations and K-CVD model applied as complementary tools. Outcomes The primary outcome is time to the first occurrence of a four-component major adverse cardiovascular event, comprising acute myocardial infarction, stroke, cardiovascular death, or coronary revascularization. Secondary outcomes include other cardiovascular events, hepatic and renal outcomes, extrahepatic malignancy, and all-cause mortality. Participants will be followed for up to 10 years with serial VCTE; repeat coronary artery calcium scoring is planned at 5 and 10 years in eligible participants. Conclusion The MASLD VCTE-C cohort is expected to provide prospective evidence on liver–cardiovascular relationships that may inform integrated risk assessment in patients with MASLD. (KCT0012473).
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7225872497
FWCI:
Cites: 37
Cited by:
Related to: 10